Bone Graft News and Research

RSS

Medtronic reports FDA Panel's affirmative votes on AMPLIFY rhBMP-2 Matrix for posterolateral spine fusion

The U.S. Food and Drug Administration (FDA) Orthopaedic and Rehabilitation Devices Panel today voted 9 for and 4 against (1 abstention) on safety and 10 for and 3 against (1 abstention) on effectiveness, that data including results from a large, prospective randomized clinical trial demonstrated the safety and effectiveness of AMPLIFY™ rhBMP-2 Matrix for fusions of the lower spine in patients with degenerative disc disease.

28 Jul 2010

Growth in dental implant sales to propel bone-graft-substitute market

According to new dental reports by iData Research, the leading global authority in medical device, dental and pharmaceutical market research, the U.S. market for dental implants is expected to regain double-digit growth by 2013, and will help drive the dental prosthetic market to reach over 82 million prosthetic placements by 2016.

27 Jul 2010

BioMimetic Therapeutics closes underwritten public offering

BioMimetic Therapeutics, Inc., announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised their option to purchase an additional approximately 642,000 shares of common stock. As a result, BioMimetic sold a total of approximately 5.64 million shares of its common stock at a price to the public of $8.50 per share.

21 Jul 2010

BioMimetic reports final study results comparing Augment Bone Graft to autograft in foot, ankle fusion surgery

BioMimetic Therapeutics will report today the final, one year results of its North American Pivotal Study comparing Augment Bone Graft to autograft in foot and ankle fusion surgery. The presentation of the data by Dr. Timothy Daniels, associate professor of orthopedic surgery at the University of Toronto and St. Michaels Hospital, will take place at the American Orthopaedic Foot and Ankle Society (AOFAS) summer meeting.

8 Jul 2010

Biomimetic Therapeutics to discuss Augment Bone Graft data results at AOFAS meeting

BioMimetic Therapeutics, Inc. today announced its schedule of events at the American Orthopaedic Foot and Ankle Society (AOFAS) summer meeting being held at the Gaylord National Hotel and Convention Center in National Harbor, Maryland from July 7 - 10, 2010.

2 Jul 2010

Bacterin International completes reverse merger transaction

Bacterin International, Inc., a Nevada company, today announced that it has completed a reverse merger transaction with Bacterin International Holdings, Inc. f/k/a K-Kitz, in which the Company caused its wholly-owned subsidiary to be merged with and into Bacterin, with Bacterin as the surviving company.

1 Jul 2010

Cerapedics' i-FACTOR Flex bone graft product line receives CE Mark

Cerapedics, Inc., a medical device company focused on developing and commercializing novel osteobiologic products, announced today that it received the CE Mark for its i-FACTOR™ Flex bone graft product line. i-FACTOR Flex is the company's second product in the i-FACTOR product platform based on its proprietary small peptide attachment factor technology.

30 Jun 2010

FDA accepts for review BioMimetic Therapeutics' Augment Bone Graft PMA application

BioMimetic Therapeutics, Inc. today announced the Food & Drug Administration (FDA) has accepted for review its Premarket Approval (PMA) application for Augment™ Bone Graft for use in foot and ankle fusions in the U.S. The FDA has now filed the application and begun the comprehensive review of the clinical module.

29 Jun 2010

Bacterin International to distribute biologic products to Broadlane network of medical institutions

Bacterin International, Inc., a developer of revolutionary bone graft material, today announced a three-year agreement to provide its biologic line of products, OsteoSponge®, OsteoSelect®, OsteoSponge SC®, OsteoWrap®, BacFast®, and OsteoLock®, to the vast Broadlane® nationwide network of hospitals and medical practices.

17 Jun 2010

Integra LifeSciences announces over 800 implantations of Vu a-POD fusion device

Integra LifeSciences announced today a major milestone in the commercialization of the Vu a-POD™ anterior lumbar intervertebral body fusion (ALIF) device. Launched in the U.S. in early 2009, the Vu a-Pod™ fusion device has now been implanted in over 800 patients in the U.S.

8 Jun 2010

Osteotech reports overall sequential revenue growth of 117% for first-quarter 2010

Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, today reported financial results for the first quarter ended March 31, 2010.

10 May 2010

RTI Biologics reports revenues of $37.8M for first-quarter 2010

RTI Biologics Inc., a leading processor of orthopedic and other biologic implants, reported operating results for the first quarter ending March 31, 2010

29 Apr 2010

Baxter International's global sales for first-quarter advances by 11% to $3.1 billion

Baxter International Inc. today reported first quarter net income of $525 million, an increase of 2 percent from $516 million reported in the first quarter of 2009. Earnings per diluted share of $0.86 increased 4 percent from $0.83 per diluted share reported in the prior-year period. Baxter's first quarter financial results included a one-time, non-cash special charge of $39 million (or $0.07 per diluted share) related to a change in the tax treatment of post-retirement prescription drug benefits under recent U.S. healthcare reform legislation.

From Baxter International Inc. 22 Apr 2010

Bone stem cells could become a part of new, innovative hip replacement treatment

Bone stem cells could in future be used instead of bone from donors as part of an innovative new hip replacement treatment, according to scientists at the University of Southampton.

24 Mar 2010

ACL knee reconstruction patients well and active after 15 years

Eighty-four percent of males who had ACL knee (anterior cruciate ligament) reconstruction with a patellar tendon (the tendon that attaches the knee to the front of the tibia or shin bone) graft continue at a high level of activity 15 years later, according to a study presented today at the American Orthopaedic Society for Sports Medicine's Specialty Day in New Orleans, Louisiana (March 13). Additionally, these patients have not developed severe osteoarthritis and their knees remain stable.

15 Mar 2010

Artificial periosteum heals serious bone injuries

A husband and wife research team has found a way to use the sleeve-like cover on bone to heal serious bone injuries faster and more simply than current methods. And they've developed an artificial sleeve that spurs fast healing when a car wreck, bomb blast or disease leaves too little cover.

10 Mar 2010

ETEX receives FDA marketing clearance for CarriGen Porous Bone Substitute Material

ETEX Corporation, an advanced biomaterials company, announced today that the FDA has granted 510(k) clearance of CarriGen® Porous Bone Substitute Material. CarriGen is available for immediate sale through ETEX's independent sales force. CarriGen builds upon the clinically proven benefit of ETEX nanocrystalline calcium phosphate technology by adding the advantage of increased porosity and pore size. CarriGen is the first highly porous bone graft substitute that sets hard upon implantation for a complete defect fill.

9 Mar 2010

Osteotech's MagniFuse Bone Graft generates $1M in revenue

Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that its MagniFuse™ Bone Graft has generated its first $1 million in revenue during the four month period beginning with the limited launch of the product in late October 2009. Osteotech began the first phase of its strategic limited launch of MagniFuse with the release of three procedure specific forms for posterior cervical and posterolateral spine fusion and spinal deformity procedures.

8 Mar 2010

Baxter International to acquire outstanding equity of ApaTech for $330 million

Baxter International Inc., a global, diversified healthcare company, and ApaTech, a private equity-backed, U.K.-based orthobiologic products company, today announced a definitive agreement whereby Baxter will acquire all of the outstanding equity of ApaTech for total consideration of up to $330 million.

From Baxter International Inc. 2 Mar 2010

BioMimetic Therapeutics annouces completion of Augment Bone Graft PMA submission

BioMimetic Therapeutics, Inc. today announced it has submitted the third and final module of its Premarket Approval (PMA) application for marketing of Augment™ Bone Graft in the U.S. This final module, containing a comprehensive review of the clinical data related to Augment, completes the PMA application to the FDA. The Company previously announced the filing of both the pre-clinical pharmacology/toxicology and quality/manufacturing modules with the FDA in June of 2009.

18 Feb 2010